The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy.

ABSTRACT:

Background

Early tumor shrinkage (ETS) has been identified as a promising imaging biomarker for patients undergoing immunotherapy for several cancer entities. This study aimed to validate the potential of ETS as an imaging biomarker for patients undergoing immunotherapy for hepatocellular carcinoma (HCC).

Methods

We screened all patients with HCC that received immunotherapy as the first or subsequent line of treatment at our tertiary care center between 2016 and 2021. ETS was defined as the reduction in the sum of the sizes of target lesions, between the initial imaging and the first follow-up. The ETS was compared to the radiologic response, according to the modified response evaluation criteria in solid tumors (mRECIST). Furthermore, we evaluated the influence of ETS on ov

SUBMITTER: Muller L 

PROVIDER: S-EPMC9509639 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature